Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1224 clinical trials
Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer

inferior to lobectomy for cT1N0M0 non-small-cell lung cancer or not.

lung carcinoma
  • 0 views
  • 22 Jan, 2021
  • 1 location
KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer

This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of KN046 plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin in subjects with advanced squamous NSCLC who have not previously received systemic treatment.

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC)

The purpose of this phase 1/2 study is to evaluate the safety, recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs), maximum tolerated dose (MTD), pharmacokinetics of oral TAK-788 and its active metabolites, anti-tumor activity of TAK-788 in participants with NSCLC with epidermal growth factor receptor (EGFR) or human epidermal …

growth factor
metastasis
HER2
epidermal growth factor receptor
afatinib
  • 0 views
  • 27 Jan, 2021
  • 98 locations
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.

lung carcinoma
durvalumab
chemoradiotherapy
  • 284 views
  • 26 Apr, 2021
  • 146 locations
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

-small cell lung cancer compared to the combination of paclitaxel and carboplatin alone

paclitaxel
stage iv non-small cell lung cancer
carboplatin
  • 10 views
  • 07 Nov, 2020
  • 1 location
SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Primary Objectives: Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: To assess the …

squamous non-small cell lung cancer
measurable disease
cancer
platinum-based chemotherapy
  • 0 views
  • 16 Apr, 2021
  • 12 locations
Safety Tolerability Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Xenograft mouse model. This study aims at local advanced or metastatic non-small cell lung cancer patients with T790M drug-resistant mutation.

  • 32 views
  • 25 Jan, 2021
  • 3 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

growth factor
epidermal growth factor receptor
lung carcinoma
osimertinib
solid tumour
  • 27 views
  • 11 Apr, 2021
  • 298 locations
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

stereotactic body radiation therapy
lung carcinoma
durvalumab
  • 68 views
  • 28 Apr, 2021
  • 227 locations
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B and C), to estimate the antitumor activity of

growth factor
epidermal growth factor receptor
platinum-based chemotherapy
afatinib
lung carcinoma
  • 5 views
  • 09 Apr, 2021
  • 84 locations